Literature DB >> 10722526

In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

S Strigl1, P M Roblin, T Reznik, M R Hammerschlag.   

Abstract

The in vitro activities of ABT 773, telithromycin (HMR 3647), azithromycin, clarithromycin, erythromycin, and levofloxacin were tested against 20 strains of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by ABT 773 were 0.015 microg/ml (range, 0.008 to 0.015 microg/ml). ABT 773 was the most active antibiotic tested in this study.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10722526      PMCID： PMC89827          DOI： 10.1128/AAC.44.4.1112-1113.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

Authors:  F J Boswell; J M Andrews; J P Ashby; C Fogarty; N P Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

2.  In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.

Authors:  C Agouridas; A Bonnefoy; J F Chantot
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  In-vitro activity of ketolides against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; M D Aydin; J F Chantot; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

6.  In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

Authors:  R R Reinert; A Bryskier; R Lütticken
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors:  S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129
  10 in total
  9 in total

1.  Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Authors:  A M Nilius; M H Bui; L Almer; D Hensey-Rudloff; J Beyer; Z Ma; Y S Or; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Authors:  Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

4.  In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; F Higa; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Authors:  Martina Bosnar; Zeljko Kelnerić; Vesna Munić; Vesna Eraković; Michael J Parnham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 7.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.